Generated by AI
Exagen Inc. is a commercial-stage diagnostics company specializing in autoimmune testing solutions under the AVISE brand in the United States. It designs, develops, and commercializes testing products that enable healthcare providers to diagnose, prognose, and monitor complex rheumatic and autoimmune diseases, such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and other connective tissue diseases (CTDs). The lead product, AVISE CTD, supports differential diagnosis for patients with overlapping symptoms of various CTDs. Exagen Inc. also offers specialized biomarkers, including those for seronegative rheumatoid arthritis like anti-PAD4 markers and urinary panels for lupus nephritis, enhancing clinical utility in rheumatology. These tests play a key role in improving patient care by facilitating timely interventions and optimizing therapeutic strategies within the autoimmune diagnostics market. Headquartered in Carlsbad, California, Exagen Inc. focuses on advancing laboratory testing adoption among rheumatologists and supports research through presentations at medical conferences.
Website1261 Liberty Way
Vista, CA, 92081
United States
The latest articles about XGN.
Analyst rates Exagen (XGN) stock a Hold, as Q3 revenue grew 7% year over year but fell 8% sequentially.
Exagen Inc (XGN) posted its best-ever third quarter with $18.4 million in revenue, record $451 ASP, and 85% Pharma Services growth, while teeing up its highly anticipated myositis test for early 2027.
Summary of Aug 4's posts. Generated by AI.
Summary of Jun 10's posts. Generated by AI.
Summary of Aug 4's posts. Generated by AI.
Investors talking about XGN also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.